Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketMovers.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent INBS Stock Price: $1.20
Summary: Intelligent Bio Solutions Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Intelligent Bio Solutions Inc., formerly known as GBS Inc., is based in NEW YORK.
analyst at reiterates coverage on Intelligent Bio Solutions (INBS) stock in the energy sector with a rating and has set INBS's stock price target at .
TipRanks.com reports that Intelligent Bio Solutions currently has n/a analysts offering 12-month price targets on INBS and the consensus is a n/a rating with an average stock price target of n/a. The most recent INBS stock price we have is $1.20 and we are not making any INBS forecasts at this time.
In addition, TradingView issued a Strong Buy rating for INBS over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on INBS. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on INBS, please click here >>
DermTech, DMTK
Recent DMTK Stock Price: $6.10
Summary: DermTech Inc. markets and develops products which facilitate early detection of skin cancers, assess inflammatory diseases and customize drug treatments. DermTech Inc., formerly known as Constellation Alpha Capital Corp., is based in La Jolla, United States.
analyst at reiterates coverage on DermTech (DMTK) stock in the energy sector with a rating and has set DMTK's stock price target at .
TipRanks.com reports that DermTech currently has 5 analysts offering 12-month price targets on DMTK and the consensus is a Strong Buy rating with an average stock price target of $6.25. The most recent DMTK stock price we have is $6.10 and we are not making any DMTK forecasts at this time.
In addition, TradingView issued a Buy rating for DMTK over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DMTK. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DMTK, please click here >>
NeuroPace, NPCE
Recent NPCE Stock Price: $3.47
Summary: NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.
analyst at reiterates coverage on NeuroPace (NPCE) stock in the energy sector with a rating and has set NPCE's stock price target at .
TipRanks.com reports that NeuroPace currently has 2 analysts offering 12-month price targets on NPCE and the consensus is a Hold rating with an average stock price target of $4.25. The most recent NPCE stock price we have is $3.47 and we are not making any NPCE forecasts at this time.
In addition, TradingView issued a Buy rating for NPCE over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on NPCE. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NPCE, please click here >>
Biora Therapeutics, BIOR
Recent BIOR Stock Price: $4.44
Summary: Biora Therapeutics Inc. is a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond. Biora Therapeutics Inc., formerly known as Progenity Inc., is based in SAN DIEGO.
analyst at reiterates coverage on Biora Therapeutics (BIOR) stock in the energy sector with a rating and has set BIOR's stock price target at .
TipRanks.com reports that Biora Therapeutics currently has 1 analysts offering 12-month price targets on BIOR and the consensus is a Moderate Buy rating with an average stock price target of $65.00. The most recent BIOR stock price we have is $4.44 and we are not making any BIOR forecasts at this time.
In addition, TradingView issued a Neutral rating for BIOR over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BIOR. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIOR, please click here >>
The editors at financialmarketmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketMovers.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================